(Q33392786)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1 reference

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Birgit Gruenberger

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Johannes Schueller

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ute Heubrandtner

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Fritz Wrba

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Klaus Kaczirek

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Rudolf Roka

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Sandra Freimann-Pircher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Thomas Gruenberger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

9 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1142-1148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

The epidemiology of cholangiocarcinoma

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

A review and update on cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

1 reference

7 January 2021

Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Phase II study of erlotinib in patients with advanced biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Molecular targeted therapy of biliary tract cancer--results of the first clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970247-3

7 January 2021

10.1016/S1470-2045(10)70247-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21071270%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference